Not available
Quote | Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)
Last: | $143.80 |
---|---|
Change Percent: | -0.36% |
Open: | $146.6 |
Close: | $143.80 |
High: | $147.486 |
Low: | $143.52 |
Volume: | 388,114 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Management will provide an update on the C...
2024-04-10 12:03:39 ET More on Ionis Pharmaceuticals Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain Ionis Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Ionis Pharmaceuticals, Inc. (IONS) Q4 2023 Earnings Call Transc...
Message Board Posts | Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $ALNY News Article - Alnylam to Present Additional Data from the APOLLO-B Phase 3 Study | whytestocks | investorshangout | 09/13/2022 12:25:48 PM |
whytestocks: $ALNY News Article - Alnylam Announces Pricing of Offering of $900 Million Convertible | whytestocks | investorshangout | 09/13/2022 12:20:47 PM |
whytestocks: $ALNY News Article - Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study | whytestocks | investorshangout | 09/08/2022 4:15:54 PM |
whytestocks: $ALNY News Article - Alnylam to Webcast Presentation at Morgan Stanley 20th Annual Glob | whytestocks | investorshangout | 09/06/2022 12:20:48 PM |
whytestocks: $ALNY News Article - Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Bo | whytestocks | investorshangout | 08/24/2022 8:06:00 PM |
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Management will provide an update on the C...
On Sunday, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) presented results from the KARDIA-2 Phase 2 study, which evaluated the efficacy and...
– Study Met Primary Endpoint Demonstrating Clinically Significant Additive Reductions in Ambulatory Systolic Blood Pressure of Up to 12.1 mmHg Across Three Independent Study Cohorts at Month 3 – – A Single Dose of Zilebesiran Resulted in Clinically Significant Additiv...